

# Casper H J Van Eijck

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6946419/publications.pdf>

Version: 2024-02-01

156  
papers

8,640  
citations

66234

42  
h-index

49773

87  
g-index

156  
all docs

156  
docs citations

156  
times ranked

8659  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term yield of pancreatic cancer surveillance in high-risk individuals. <i>Gut</i> , 2022, 71, 1152-1160.	6.1	84
2	International Validation of a Nomogram to Predict Recurrence after Resection of Grade 1 and 2 Nonfunctioning Pancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2022, 112, 571-579.	1.2	6
3	The impact of cancer treatment on quality of life in patients with pancreatic and periampullary cancer: a propensity score matched analysis. <i>Hpb</i> , 2022, 24, 443-451.	0.1	5
4	Impact of Complications After Pancreatoduodenectomy on Mortality, Organ Failure, Hospital Stay, and Readmission. <i>Annals of Surgery</i> , 2022, 275, e222-e228.	2.1	38
5	Surgical Complications in a Multicenter Randomized Trial Comparing Preoperative Chemoradiotherapy and Immediate Surgery in Patients With Resectable and Borderline Resectable Pancreatic Cancer (PREOPANC Trial). <i>Annals of Surgery</i> , 2022, 275, 979-984.	2.1	26
6	Quality of life of locally advanced pancreatic cancer patients after FOLFIRINOX treatment. <i>Supportive Care in Cancer</i> , 2022, 30, 2407-2415.	1.0	2
7	Sensitivity of CT, MRI, and EUS-FNA/B in the preoperative workup of histologically proven left-sided pancreatic lesions. <i>Pancreatology</i> , 2022, 22, 136-141.	0.5	3
8	Incidence and impact of postoperative pancreatic fistula after minimally invasive and open distal pancreatectomy. <i>Surgery</i> , 2022, 171, 1658-1664.	1.0	12
9	FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium. <i>Journal of the National Cancer Institute</i> , 2022, 114, 695-703.	3.0	20
10	Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1220-1230.	0.8	274
11	Routine abdominal drainage after distal pancreatectomy: meta-analysis. <i>British Journal of Surgery</i> , 2022, 109, 486-488.	0.1	6
12	Trends in Staging, Treatment, and Survival in Colorectal Cancer Between 1990 and 2014 in the Rotterdam Study. <i>Frontiers in Oncology</i> , 2022, 12, 849951.	1.3	2
13	The Class I HDAC Inhibitor Valproic Acid Strongly Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Immune System Activation. <i>Biomedicines</i> , 2022, 10, 517.	1.4	7
14	Therapeutic anticoagulation for splanchnic vein thrombosis in acute pancreatitis: A systematic review and meta-analysis. <i>Pancreatology</i> , 2022, 22, 235-243.	0.5	15
15	Sex, Gender and Age Differences in Treatment Allocation and Survival of Patients With Metastatic Pancreatic Cancer: A Nationwide Study. <i>Frontiers in Oncology</i> , 2022, 12, 839779.	1.3	9
16	Rintatolimod (Ampligen®) Enhances Numbers of Peripheral B Cells and Is Associated with Longer Survival in Patients with Locally Advanced and Metastasized Pancreatic Cancer Pre-Treated with FOLFIRINOX: A Single-Center Named Patient Program. <i>Cancers</i> , 2022, 14, 1377.	1.7	1
17	Induction therapy with <sup>177</sup> Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3203-3214.	3.3	8
18	Age and prognosis in patients with pancreatic cancer: a population-based study. <i>Acta Oncol</i> , 2022, 61, 286-293.	0.8	10

#	ARTICLE	IF	CITATIONS
19	Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB). <i>JAMA Oncology</i> , 2022, 8, 929.	3.4	4
20	Algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection in the Netherlands: an open-label, nationwide, stepped-wedge cluster-randomised trial. <i>Lancet, The</i> , 2022, 399, 1867-1875.	6.3	59
21	Immunomodulatory antitumor effect of interferon-β combined with gemcitabine in pancreatic cancer. <i>International Journal of Oncology</i> , 2022, 61, .	1.4	2
22	Treatment Response and Conditional Survival in Advanced Pancreatic Cancer Patients Treated with FOLFIRINOX: A Multicenter Cohort Study. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	0.6	5
23	Pancreatic resection in the pediatric, adolescent and young adult population: nationwide analysis on complications. <i>Hpb</i> , 2021, 23, 1175-1184.	0.1	3
24	Reliability and Agreement of Radiological and Pathological Tumor Size in Patients with Multiple Endocrine Neoplasia Type 1-Related Pancreatic Neuroendocrine Tumors: Results from a Population-Based Cohort. <i>Neuroendocrinology</i> , 2021, 111, 705-717.	1.2	13
25	Surgical management and pathological assessment of pancreatoduodenectomy with venous resection: an international survey among surgeons and pathologists. <i>Hpb</i> , 2021, 23, 80-89.	0.1	9
26	Quality and performance of validated prognostic models for survival after resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. <i>Hpb</i> , 2021, 23, 25-36.	0.1	16
27	Impact of Borderline Resectability in Pancreatic Head Cancer on Patient Survival: Biology Matters According to the New International Consensus Criteria. <i>Annals of Surgical Oncology</i> , 2021, 28, 2325-2336.	0.7	21
28	Venous wedge and segment resection during pancreatoduodenectomy for pancreatic cancer: impact on short- and long-term outcomes in a nationwide cohort analysis. <i>British Journal of Surgery</i> , 2021, 109, 96-104.	0.1	16
29	Indications and outcomes of enucleation versus formal pancreatectomy for pancreatic neuroendocrine tumors. <i>Hpb</i> , 2021, 23, 413-421.	0.1	18
30	Type I interferons in pancreatic cancer and development of new therapeutic approaches. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 159, 103204.	2.0	18
31	Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. <i>Scientific Reports</i> , 2021, 11, 7570.	1.6	2
32	Identifying Risk Factors and Patterns for Early Recurrence of Pancreatic Neuroendocrine Tumors: A Multi-Institutional Study. <i>Cancers</i> , 2021, 13, 2242.	1.7	6
33	The value of serum amylase and drain fluid amylase to predict postoperative pancreatic fistula after pancreatoduodenectomy: a retrospective cohort study. <i>Langenbeck's Archives of Surgery</i> , 2021, 406, 2333-2341.	0.8	4
34	Preoperative serum ADAM12 levels as a stromal marker for overall survival and benefit of adjuvant therapy in patients with resected pancreatic and periampullary cancer. <i>Hpb</i> , 2021, 23, 1886-1896.	0.1	3
35	The effect of preoperative chemotherapy and chemoradiotherapy on pancreatic fistula and other surgical complications after pancreatic resection: a systematic review and meta-analysis of comparative studies. <i>Hpb</i> , 2021, 23, 1321-1331.	0.1	16
36	Rintatolimod Induces Antiviral Activities in Human Pancreatic Cancer Cells: Opening for an Anti-COVID-19 Opportunity in Cancer Patients?. <i>Cancers</i> , 2021, 13, 2896.	1.7	5

#	ARTICLE	IF	CITATIONS
37	ASO Visual Abstract: Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer – A Systematic Review and Meta-analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 485-487.	0.7	1
38	Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 8297-8308.	0.7	19
39	Differential Expression of BOC, SPOCK2, and GJD3 Is Associated with Brain Metastasis of ER-Negative Breast Cancers. <i>Cancers</i> , 2021, 13, 2982.	1.7	4
40	Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only. <i>Annals of Surgery</i> , 2021, 274, 729-735.	2.1	13
41	The bigger picture of shared decision making: A service design perspective using the care path of locally advanced pancreatic cancer as a case. <i>Cancer Medicine</i> , 2021, 10, 5907-5916.	1.3	22
42	The Impact of Neoadjuvant Treatment on Survival in Patients Undergoing Pancreatoduodenectomy With Concomitant Portomesenteric Venous Resection: An International Multicenter Analysis. <i>Annals of Surgery</i> , 2021, 274, 721-728.	2.1	24
43	Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. <i>Frontiers in Genetics</i> , 2021, 12, 693933.	1.1	10
44	Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. <i>Trials</i> , 2021, 22, 608.	0.7	22
45	Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2342-2345.	1.1	4
46	Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 6602-6612.	3.2	22
47	Preoperative misdiagnosis of pancreatic and periampullary cancer in patients undergoing pancreatoduodenectomy: A multicentre retrospective cohort study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2525-2532.	0.5	21
48	Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110337.	1.4	8
49	Complications After Major Surgery for Duodenopancreatic Neuroendocrine Tumors in Patients with MEN1: Results from a Nationwide Cohort. <i>Annals of Surgical Oncology</i> , 2021, 28, 4387-4399.	0.7	12
50	Endoscopic ultrasonography as additional preoperative workup is valuable in half of the patients with a pancreatic body or tail lesion. <i>Hpb</i> , 2021, , .	0.1	0
51	Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10902.	1.8	9
52	Abstract PO-118: The tumor immune microenvironment is decisive in the survival of pancreatic ductal adenocarcinoma. , 2021, , .		0
53	Abstract PO-046: The effect of neoadjuvant therapy on immune profiling of pancreatic ductal adenocarcinoma: A prospective study of the PREOPANC-1 randomized controlled trial. , 2021, , .		0
54	Robust deep learning model for prognostic stratification of pancreatic ductal adenocarcinoma patients. <i>IScience</i> , 2021, 24, 103415.	1.9	6

#	ARTICLE	IF	CITATIONS
55	The Placental Innate Immune System Is Altered in Early-Onset Preeclampsia, but Not in Late-Onset Preeclampsia. <i>Frontiers in Immunology</i> , 2021, 12, 780043.	2.2	13
56	Screening for colorectal cancer after pancreatoduodenectomy for ampullary cancer. <i>European Journal of Surgical Oncology</i> , 2020, 46, 534-538.	0.5	0
57	Early recognition of clinically relevant postoperative pancreatic fistula: a systematic review. <i>Hpb</i> , 2020, 22, 1-11.	0.1	32
58	International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer. <i>European Journal of Surgical Oncology</i> , 2020, 46, 796-803.	0.5	14
59	The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis. <i>Hpb</i> , 2020, 22, 233-240.	0.1	66
60	Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2020, 125, 83-93.	1.3	98
61	Defining Benchmark Outcomes for Pancreatoduodenectomy With Portomesenteric Venous Resection. <i>Annals of Surgery</i> , 2020, 272, 731-737.	2.1	49
62	C-reactive protein is superior to white blood cell count for early detection of complications after pancreatoduodenectomy: a retrospective multicenter cohort study. <i>Hpb</i> , 2020, 22, 1504-1512.	0.1	12
63	Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model. , 2020, 8, e000772.		36
64	Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data. <i>Frontiers in Oncology</i> , 2020, 10, 1112.	1.3	12
65	Clinical relevance of performing endoscopic ultrasound-guided fine-needle biopsy for pancreatic neuroendocrine tumors less than 2 cm. <i>Journal of Surgical Oncology</i> , 2020, 122, 1393-1400.	0.8	15
66	Cachexia, dietetic consultation, and survival in patients with pancreatic and periampullary cancer: A multicenter cohort study. <i>Cancer Medicine</i> , 2020, 9, 9385-9395.	1.3	12
67	Nationwide compliance with a multidisciplinary guideline on pancreatic cancer during 6-year follow-up. <i>Pancreatology</i> , 2020, 20, 1723-1731.	0.5	9
68	Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer. <i>BMC Cancer</i> , 2020, 20, 913.	1.1	11
69	Care after pancreatic resection according to an algorithm for early detection and minimally invasive management of pancreatic fistula versus current practice (PORSCH-trial): design and rationale of a nationwide stepped-wedge cluster-randomized trial. <i>Trials</i> , 2020, 21, 389.	0.7	21
70	Establishing and Coordinating a Nationwide Multidisciplinary Study Group: Lessons Learned by the Dutch Pancreatic Cancer Group. <i>Annals of Surgery</i> , 2020, 271, e102-e104.	2.1	43
71	Serum miR-338-3p and miR-199b-5p are associated with the absolute neutrophil count in patients with resectable pancreatic cancer. <i>Clinica Chimica Acta</i> , 2020, 505, 183-189.	0.5	11
72	Patient-reported burden of intensified surveillance and surgery in high-risk individuals under pancreatic cancer surveillance. <i>Familial Cancer</i> , 2020, 19, 247-258.	0.9	7

#	ARTICLE	IF	CITATIONS
73	RNA from stabilized whole blood enables more comprehensive immune gene expression profiling compared to RNA from peripheral blood mononuclear cells. PLoS ONE, 2020, 15, e0235413.	1.1	14
74	Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. Journal of Clinical Oncology, 2020, 38, 1763-1773.	0.8	665
75	Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis. Acta Oncologica, 2020, 59, 705-712.	0.8	9
76	Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model. Annals of Surgical Oncology, 2020, 27, 2516-2524.	0.7	36
77	Effect of Early Surgery vs Endoscopy-First Approach on Pain in Patients With Chronic Pancreatitis. JAMA - Journal of the American Medical Association, 2020, 323, 237.	3.8	138
78	Pathological validation and prognostic potential of quantitative MRI in the characterization of pancreas cancer: preliminary experience. Molecular Oncology, 2020, 14, 2176-2189.	2.1	23
79	External Validity of the Multicenter Randomized PREOPANC Trial on Neoadjuvant Chemoradiotherapy in Pancreatic Cancer. Annals of Surgery, 2020, Publish Ahead of Print, .	2.1	4
80	Postoperative parathyroid hormone levels as a predictor for persistent hypoparathyroidism. European Journal of Endocrinology, 2020, 183, 149-159.	1.9	12
81	Patient Satisfaction and Quality of Life Before and After Treatment of Pancreatic and Periampullary Cancer: A Prospective Multicenter Study. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 704-711.	2.3	14
82	Relationship Between Quality of Life and Survival in Patients With Pancreatic and Periampullary Cancer: A Multicenter Cohort Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1354-1363.	2.3	11
83	Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. Cancers, 2019, 11, 976.	1.7	63
84	Outcome and long-term quality of life after total pancreatectomy (PANORAMA): a nationwide cohort study. Surgery, 2019, 166, 1017-1026.	1.0	43
85	Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients. Cancers, 2019, 11, 93.	1.7	22
86	Search for Early Pancreatic Cancer Blood Biomarkers in Five European Prospective Population Biobanks Using Metabolomics. Endocrinology, 2019, 160, 1731-1742.	1.4	19
87	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Journal of the National Cancer Institute, 2019, 111, 782-794.	3.0	223
88	Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers, 2019, 11, 588.	1.7	42
89	Video-assisted thoracic lobectomy versus stereotactic body radiotherapy for stage I nonsmall cell lung cancer in elderly patients: a propensity matched comparative analysis. European Respiratory Journal, 2019, 53, 1801561.	3.1	24
90	Superiority of Step-up Approach vs Open Necrosectomy in Long-term Follow-up of Patients With Necrotizing Pancreatitis. Gastroenterology, 2019, 156, 1016-1026.	0.6	145

#	ARTICLE	IF	CITATIONS
91	Immune-Related Circulating miR-125b-5p and miR-99a-5p Reveal a High Recurrence Risk Group of Pancreatic Cancer Patients after Tumor Resection. <i>Applied Sciences (Switzerland)</i> , 2019, 9, 4784.	1.3	4
92	Efficacy and feasibility of stereotactic radiotherapy after folfinox in patients with locally advanced pancreatic cancer (LAPC-1 trial). <i>EclinicalMedicine</i> , 2019, 17, 100200.	3.2	41
93	Predicting Successful Catheter Drainage in Patients With Pancreatic Fistula After Pancreatoduodenectomy. <i>Pancreas</i> , 2019, 48, 811-816.	0.5	4
94	Minimally Invasive Versus Open Distal Pancreatectomy (LEOPARD). <i>Annals of Surgery</i> , 2019, 269, 2-9.	2.1	401
95	Alternative Fistula Risk Score for Pancreatoduodenectomy (a-FRS). <i>Annals of Surgery</i> , 2019, 269, 937-943.	2.1	257
96	Minimally Invasive versus Open Distal Pancreatectomy for Ductal Adenocarcinoma (DIPLOMA). <i>Annals of Surgery</i> , 2019, 269, 10-17.	2.1	211
97	The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels. <i>Annals of Surgery</i> , 2019, 270, 139-146.	2.1	179
98	Variation in hospital mortality after pancreatoduodenectomy is related to failure to rescue rather than major complications: a nationwide audit. <i>Hpb</i> , 2018, 20, 759-767.	0.1	85
99	Early and Late Complications After Surgery for MEN1-related Nonfunctioning Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2018, 267, 352-356.	2.1	46
100	A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Nonfunctional Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2018, 267, 1148-1154.	2.1	101
101	Endoscopic or surgical step-up approach for infected necrotising pancreatitis: a multicentre randomised trial. <i>Lancet, The</i> , 2018, 391, 51-58.	6.3	504
102	Patients with chronic mesenteric ischemia have an altered sublingual microcirculation. <i>Clinical and Experimental Gastroenterology</i> , 2018, Volume 11, 405-414.	1.0	5
103	Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis. <i>Acta Oncol</i> , 2018, 57, 1655-1662.	0.8	70
104	International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer. <i>JAMA Surgery</i> , 2018, 153, e183617.	2.2	213
105	Trends in treatment and survival of patients with nonresected, nonmetastatic pancreatic cancer: A population-based study. <i>Cancer Medicine</i> , 2018, 7, 4943-4951.	1.3	23
106	New-onset diabetes after pancreatoduodenectomy: A systematic review and meta-analysis. <i>Surgery</i> , 2018, 164, 6-16.	1.0	27
107	Management of postoperative pancreatic fistula after pancreatoduodenectomy: high mortality after completion pancreatectomy. <i>Hpb</i> , 2018, 20, 1223.	0.1	1
108	Changes in treatment patterns and survival in elderly patients with stage I non-small-cell lung cancer with the introduction of stereotactic body radiotherapy and video-assisted thoracic surgery. <i>European Journal of Cancer</i> , 2018, 101, 30-37.	1.3	22

#	ARTICLE	IF	CITATIONS
109	Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a multicentre, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 681-690.	3.7	126
110	Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve follow-up after curative surgical resection of well-differentiated pancreatic neuroendocrine tumors. <i>Journal of Surgical Oncology</i> , 2018, 118, 37-48.	0.8	30
111	Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2018, 2018, .	0.2	12
112	Management of Severe Pancreatic Fistula After Pancreatoduodenectomy. <i>JAMA Surgery</i> , 2017, 152, 540.	2.2	96
113	Minimally invasive versus open distal pancreatectomy (LEOPARD): study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 166.	0.7	40
114	Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 4617-4624.	3.2	399
115	Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 630-638.	1.0	7
116	Nationwide prospective audit of pancreatic surgery: design, accuracy, and outcomes of the Dutch Pancreatic Cancer Audit. <i>Hpb</i> , 2017, 19, 919-926.	0.1	97
117	Pancreatic Duct Obstruction in a Middle-Aged Woman: A Case Report. <i>Journal of Pancreatic Cancer</i> , 2017, 3, 13-14.	1.6	1
118	A Rare Tumor in the Common Bile Duct: A Case Report. <i>Journal of Pancreatic Cancer</i> , 2017, 3, 10-12.	1.6	1
119	Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 56816-56828.	0.8	32
120	Pancreatic Duct Obstruction in a Middle-Aged Woman: A Case Report. <i>Journal of Pancreatic Cancer</i> , 2017, 3, 13-14.	1.6	0
121	Potential of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib. <i>Theranostics</i> , 2016, 6, 1821-1832.	4.6	100
122	Impact of parathyroidectomy for primary hyperparathyroidism on quality of life: A case-control study using Short Form Health Survey 36. <i>Head and Neck</i> , 2016, 38, 1213-1220.	0.9	15
123	Gastric Outlet Obstruction. <i>JAMA Surgery</i> , 2016, 151, 577.	2.2	0
124	Pancreatoduodenectomy with colon resection for cancer: A nationwide retrospective analysis. <i>Surgery</i> , 2016, 160, 145-152.	1.0	12
125	FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. <i>Lancet Oncology</i> , The, 2016, 17, 801-810.	5.1	719
126	Prognostic value of lymph node metastases detected during surgical exploration for pancreatic or periampullary cancer: a systematic review and meta-analysis. <i>Hpb</i> , 2016, 18, 559-566.	0.1	23



#	ARTICLE	IF	CITATIONS
127	Recent Advances in Pancreatic Cancer Surgery of Relevance to the Practicing Pathologist. <i>Surgical Pathology Clinics</i> , 2016, 9, 539-545.	0.7	6
128	Early biliary decompression versus conservative treatment in acute biliary pancreatitis (APEC trial): study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 5.	0.7	34
129	Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. <i>Trials</i> , 2016, 17, 127.	0.7	131
130	Postoperative Complications, In-Hospital Mortality and 5-Year Survival After Surgical Resection for Patients with a Pancreatic Neuroendocrine Tumor: A Systematic Review. <i>World Journal of Surgery</i> , 2016, 40, 729-748.	0.8	93
131	Peptide receptor radionuclide therapy of neuroendocrine tumours. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2016, 30, 103-114.	2.2	54
132	Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis. <i>Annals of Surgical Oncology</i> , 2016, 23, 585-591.	0.7	48
133	Elderly Patients Strongly Benefit from Centralization of Pancreatic Cancer Surgery: A Population-Based Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 2002-2009.	0.7	40
134	Diagnostic strategy and timing of intervention in infected necrotizing pancreatitis: an international expert survey and case vignette study. <i>Hpb</i> , 2016, 18, 49-56.	0.1	72
135	Timing of catheter drainage in infected necrotizing pancreatitis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 306-312.	8.2	83
136	Postoperative Outcomes of Enucleation and Standard Resections in Patients with a Pancreatic Neuroendocrine Tumor. <i>World Journal of Surgery</i> , 2016, 40, 715-728.	0.8	91
137	Risk of Recurrent Pancreatitis and Progression to Chronic Pancreatitis After a First Episode of Acute Pancreatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 738-746.	2.4	211
138	Subacute haematotoxicity after PRRT with <sup>177</sup> Lu-DOTA-octreotate: prognostic factors, incidence and course. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 453-463.	3.3	125
139	The accuracy of MRI, endorectal ultrasonography, and computed tomography in predicting the response of locally advanced rectal cancer after preoperative therapy: A metaanalysis. <i>Surgery</i> , 2016, 159, 688-699.	1.0	59
140	Long-term survival after resection for non-pancreatic periampullary cancer followed by adjuvant intra-arterial chemotherapy and concomitant radiotherapy. <i>Hpb</i> , 2015, 17, 573-579.	0.1	6
141	Impact of centralization of pancreatoduodenectomy on reported radical resections rates in a nationwide pathology database. <i>Hpb</i> , 2015, 17, 736-742.	0.1	34
142	Absence or low IGF1R expression in esophageal adenocarcinoma is associated with tumor invasiveness and radicality of surgical resection. <i>Journal of Surgical Oncology</i> , 2015, 111, 1047-1053.	0.8	5
143	Diagnostic strategy and timing of intervention in infected necrotizing pancreatitis: an international expert survey and case vignette study. <i>Hpb</i> , 2015, , n/a-n/a.	0.1	11
144	Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma. <i>Viruses</i> , 2015, 7, 2980-2998.	1.5	33

#	ARTICLE	IF	CITATIONS
145	Potentials of Interferon Therapy in the Treatment of Pancreatic Cancer. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 327-339.	0.5	21
146	Diagnostic value of a pancreatic mass on computed tomography in patients undergoing pancreatoduodenectomy for presumed pancreatic cancer. <i>Surgery</i> , 2015, 158, 173-182.	1.0	7
147	A Nationwide Comparison of Laparoscopic and Open Distal Pancreatectomy for Benign and Malignant Disease. <i>Journal of the American College of Surgeons</i> , 2015, 220, 263-270e1.	0.2	78
148	Preoperative endoscopic versus percutaneous transhepatic biliary drainage in potentially resectable perihilar cholangiocarcinoma (DRAINAGE trial): design and rationale of a randomized controlled trial. <i>BMC Gastroenterology</i> , 2015, 15, 20.	0.8	36
149	Same-admission versus interval cholecystectomy for mild gallstone pancreatitis (PONCHO): a multicentre randomised controlled trial. <i>Lancet, The</i> , 2015, 386, 1261-1268.	6.3	276
150	Liver Contrast-Enhanced Ultrasound Improves Detection of Liver Metastases in Patients with Pancreatic or Periampullary Cancer. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 3063-3069.	0.7	12
151	Adrenal Medullary Hyperplasia Is a Precursor Lesion for Pheochromocytoma in MEN2 Syndrome. <i>Neoplasia</i> , 2014, 16, 868-873.	2.3	55
152	mTOR is a promising therapeutical target in a subpopulation of pancreatic adenocarcinoma. <i>Cancer Letters</i> , 2014, 346, 309-317.	3.2	22
153	The role of routine fine-needle aspiration in the diagnosis of infected necrotizing pancreatitis. <i>Surgery</i> , 2014, 155, 442-448.	1.0	101
154	Detection bias may be the main cause of increased cancer incidence among diabetics: Results from the Rotterdam Study. <i>European Journal of Cancer</i> , 2014, 50, 2449-2455.	1.3	38
155	Potent Inhibitory Effects of Type I Interferons on Human Adrenocortical Carcinoma Cell Growth. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 4537-4543.	1.8	40
156	Reply to W. Attaallah, A. Jain et al, and P. Mroczkowski et al. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	1